<DOC>
	<DOCNO>NCT00283335</DOCNO>
	<brief_summary>This double-blind randomized trial comparing 1200 mg per day gemfibrozil placebo 2531 men coronary heart disease , HDL-C 40mg/dl less , LDL-C 140 mg/dl less , triglycerides 300mg/dl le . The primary outcome nonfatal myocardial infarction ( MI ) death coronary cause . The median follow-up 5.1 year . There risk reduction 22 % primary outcome ( p=.0006 ) 24 % risk reduction combine endpoint stroke , MI , CHD death . The rate event reduce raise HDL-C lower triglyceride without lower LDL-C ( N Engl J Med 1999 ; 341:410-418 ) .</brief_summary>
	<brief_title>The VA HDL Intervention Trial ( HIT ) : Secondary Prevention Coronary Heart Disease Men With Low HDL-Cholesterol Desirable LDL-Cholesterol</brief_title>
	<detailed_description>Primary Hypothesis : To determine drug treatment aim raise HDL-cholesterol lower triglyceride reduce rate heart attack death veteran coronary heart disease ( CHD ) specific lipid profile characterize normal level LDL-cholesterol low level HDL-cholesterol . Secondary Hypotheses : To determine effect treatment total mortality , unstable angina , CABG , PTCA , stroke PVD , determine whether association change plasma lipid level outcomes . Primary Outcomes : Myocardial infarction ( MI ) , silent MI , CHD death . Interventions : Gemfibrozil ( 1200 mg per day ) versus match placebo . Study Abstract : A double-blind trial conduct compare gemfibrozil placebo 2531 men coronary heart disease , HDL cholesterol level 40 mg/dL less , LDL cholesterol level 140 mg/dL less . The median follow-up 5.1 year . At one year , mean HDL 6 % high , mean triglyceride 31 % low , mean total cholesterol 4 % low gemfibrozil group placebo group . LDL level differ group . A primary event ( MI death ) occur 275 1267 placebo patient ( 21.7 % ) 219 1264 gemfibrozil patient ( 17.3 % ) . The overall reduction risk event 4.4 percentage point , reduction relative risk 22 % ( 95 % confidence interval , 7 % 35 % ; p=0.006 ) . A 24 % relative risk reduction occur combined outcome death coronary heart disease , nonfatal myocardial infarction , stroke ( p &lt; 0.001 ) . Gemfibrozil therapy result significant reduction risk major cardiovascular event patient coronary disease whose primary lipid abnormality low HDL cholesterol level . The finding suggest rate coronary event reduce raise HDL cholesterol level lower level triglyceride without lower LDL cholesterol level . The major finding publish New England Journal Medicine August , 1999 . A paper lipid screen publish Journal Clinical Epidemiology July , 1999 one clinical implication publish European Heart Journal . Our cost analysis show gemfibrozil therapy highly cost-effective cost-saving , thus provide strong rationale incorporating result clinical practice . A manuscript lipids predictor endpoint publish JAMA March , 2001 . Another paper stroke publish Circulation June , 2001 . Dr. Robins present data diabetic November , 2000 AHA . A paper cost-effectiveness publish Archives Internal Medicine January 2002 . A manuscript diabetes accepted Archives Internal Medicine . A NHLBI grant continue analysis fund two year . Other paper progress include homocysteines diabetic , fast plasma insulin predictor outcome , effect lipoprotein subclass particle size coronary event .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Gemfibrozil</mesh_term>
	<criteria>Inclusion criterion : 1. male gender 2. age 73 young 3. presence CHD 4 . HDLC le 40 mg/dl 5 . LDLC le 140 mg/dl 6. triglyceride le 300 mg/dl Exclusion criterion : 1. significant medical illness 2. alcohol substance abuse 3. evidence cholecystitis cholelithiasis 4. ejection fraction lt 35 % 5. current use steroid , estrogen , immunosuppressive agent , oral coagulant , lipid modify drug . 6. allergic gemfibrozil fibric acid 7. refuse inform consent</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>73 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>